Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
- 21 January 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Haematology
- Vol. 7 (3), e218-e225
- https://doi.org/10.1016/s2352-3026(19)30235-2
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable DiseaseJournal of Clinical Oncology, 2014
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyBlood, 2013
- Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapyCancer, 2012
- Bridging Innate and Adaptive ImmunityCell, 2011
- Harmonization of molecular monitoring of chronic myeloid leukemia therapy in JapanInternational Journal of Clinical Oncology, 2011
- The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivityInternational Journal of Cancer, 2010
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapyLeukemia, 2009
- AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid LeukemiaClinical Cancer Research, 2005